香港股市 已收市

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
88.08-0.53 (-0.59%)
市場開市。 截至 10:34AM EDT。
全螢幕
交易股價資料並非來自所有市場
前收市價88.61
開市88.34
買盤87.97 x 300
賣出價88.22 x 300
今日波幅87.93 - 88.65
52 週波幅76.02 - 100.38
成交量105,209
平均成交量1,325,206
市值16.62B
Beta 值 (5 年,每月)0.31
市盈率 (最近 12 個月)101.25
每股盈利 (最近 12 個月)0.87
業績公佈日2024年4月24日 - 2024年4月29日
遠期股息及收益率無 (無)
除息日
1 年預測目標價109.48
  • Motley Fool

    4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

    Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.

  • Reuters

    REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies

    BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the therapy maker said in a filing on Monday. The DOJ has asked the company to submit certain documents related to the sponsored testing of its therapies Vimizim and Naglazyme, BioMarin said. "We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or our other operations or programs, will not be found to violate such laws," the company said in the filing.

  • Insider Monkey

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript February 22, 2024 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.44. BMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]